These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12018776)

  • 1. A decision analytic approach to a futility analysis of a phase II pharmaceutical study.
    Pallay A
    J Biopharm Stat; 2001 Nov; 11(4):209-25. PubMed ID: 12018776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
    Glasziou PP
    Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early phase clinical trials in pediatric hematology and oncology.
    Corbacioglu S
    Klin Padiatr; 2012 Apr; 224(3):197-200. PubMed ID: 22511313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian models for subgroup analysis in clinical trials.
    Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
    Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies.
    Bruno R; Claret L
    Clin Pharmacol Ther; 2009 Aug; 86(2):136-8. PubMed ID: 19621009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing a paradigm of drug innovation: an evaluation algorithm.
    Caprino L; Russo P
    Drug Discov Today; 2006 Nov; 11(21-22):999-1006. PubMed ID: 17055409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spending on new drug development1.
    Adams CP; Brantner VV
    Health Econ; 2010 Feb; 19(2):130-41. PubMed ID: 19247981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian design and analysis for dose-response using informative prior information.
    Smith MK; Marshall S
    J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety.
    Kikuchi T; Gittins J
    Stat Med; 2009 Aug; 28(18):2293-306. PubMed ID: 19536745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 18. How do pharmaceutical companies approach data from sexual health studies for regulatory agencies?
    Dilleen M; Haughie S
    Annu Rev Sex Res; 2005; 16():53-61. PubMed ID: 16913287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are Phase 2 screening trials in oncology obsolete?
    Holmgren E
    Stat Med; 2008 Feb; 27(4):556-67. PubMed ID: 17661436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.